No Data
Lexicon Pharmaceuticals Announced New Analysis Of Phase 3 SCORED Clinical Trial Demonstrating The Protective Effects Of Sotagliflozin In Patients With Diabetic Kidney Disease
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to Be Presented at ASN Kidney Week 2024
Express News | Lexicon Pharmaceuticals Inc - Top-Line Data for Lx9211 Now Anticipated in Q1 2025
Express News | Lexicon Announces Completion of Screening in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain (Dpnp)
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Pharmaceuticals: Strategic Advancements and Growth Potential Highlighted by Exclusive Licensing Deal and Undervalued Pipeline